AZN - AstraZeneca PLC
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Cambridge,
United Kingdom
Type: Equity
AZN price evolution
AZN
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6916 | $7841 | $5840 | $4871 |
| Short term investments | $160 | $180 | $122 | $244 |
| Net receivables | $11853 | $11817 | $12929 | $12061 |
| Inventory | $5667 | $5337 | $5424 | $5292 |
| Total current assets | $25393 | $25594 | $25054 | $22501 |
| Long term investments | $1871 | $1695 | $1677 | $1290 |
| Property, plant & equipment | $10833 | $10616 | $10502 | $9700 |
| Goodwill & intangible assets | $60486 | $58812 | $58137 | $57626 |
| Total noncurrent assets | $78947 | $76699 | $76065 | $73585 |
| Total investments | $2031 | $1875 | $1799 | $1534 |
| Total assets | $104340 | $102293 | $101119 | $96086 |
| Current liabilities | ||||
| Accounts payable | $22671 | $22295 | $25034 | $22786 |
| Deferred revenue | ||||
| Short long term debt | $5359 | $6331 | $5400 | $5607 |
| Total current liabilities | $28566 | $28901 | $30542 | $28588 |
| Long term debt | $28174 | $28220 | $23222 | $22969 |
| Total noncurrent liabilities | $36176 | $35891 | $31411 | $30277 |
| Total debt | $33533 | $34551 | $28622 | $28576 |
| Total liabilities | $64742 | $64792 | $61953 | $58865 |
| Shareholders' equity | ||||
| Retained earnings | $1847 | -$212 | $1502 | -$434 |
| Other shareholder equity | ||||
| Total shareholder equity | $39512 | $37445 | $39143 | $37197 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5840 | $1411 | $6329 | $7832 |
| Short term investments | $122 | $239 | $69 | $160 |
| Net receivables | $12929 | $11252 | $10539 | $7742 |
| Inventory | $5424 | $4699 | $8983 | $4024 |
| Total current assets | $25054 | $22593 | $26244 | $19544 |
| Long term investments | $1677 | $1142 | $1237 | $1147 |
| Property, plant & equipment | $10502 | $9449 | $10171 | $8917 |
| Goodwill & intangible assets | $58137 | $59127 | $62489 | $32792 |
| Total noncurrent assets | $76065 | $73890 | $79119 | $47185 |
| Total investments | $1799 | $1381 | $1306 | $1307 |
| Total assets | $101119 | $96483 | $105363 | $66729 |
| Current liabilities | ||||
| Accounts payable | $25034 | $19040 | $23871 | $21869 |
| Deferred revenue | ||||
| Short long term debt | $5400 | $5542 | $1893 | $2386 |
| Total current liabilities | $30542 | $26293 | $22594 | $20307 |
| Long term debt | $23222 | $23690 | $28888 | $17994 |
| Total noncurrent liabilities | $31411 | $33132 | $43482 | $30784 |
| Total debt | $28622 | $29232 | $30781 | $20380 |
| Total liabilities | $61953 | $59446 | $66076 | $51091 |
| Shareholders' equity | ||||
| Retained earnings | $1502 | $1495 | $1710 | $5299 |
| Other shareholder equity | $2040 | |||
| Total shareholder equity | $39143 | $37037 | $39268 | $15622 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12938 | $12679 | $12024 | |
| Cost of revenue | $2183 | $2218 | $2308 | |
| Gross Profit | $10755 | $10461 | $9716 | |
| Operating activities | ||||
| Research & development | $3008 | $2783 | $3073 | |
| Selling, general & administrative | $5061 | $4630 | $5516 | |
| Total operating expenses | $8009 | $7346 | $8482 | |
| Operating income | $2746 | $3115 | $1234 | |
| Income from continuing operations | ||||
| EBIT | $2839 | $3212 | $1337 | |
| Income tax expense | $469 | $620 | -$62 | |
| Interest expense | $443 | $413 | $439 | |
| Net income | ||||
| Net income | $1927 | $2179 | $960 | |
| Income (for common shares) | $1927 | $2179 | $960 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $45811 | $44351 | $37417 | $26617 |
| Cost of revenue | $8268 | $12391 | $12437 | $5299 |
| Gross Profit | $37543 | $31960 | $24980 | $21318 |
| Operating activities | ||||
| Research & development | $10935 | $9762 | $9736 | $5991 |
| Selling, general & administrative | $19755 | $18955 | $15234 | $11294 |
| Total operating expenses | $29350 | $28203 | $23924 | $16156 |
| Operating income | $8193 | $3757 | $1056 | $5162 |
| Income from continuing operations | ||||
| EBIT | $8519 | $3842 | $1035 | $5222 |
| Income tax expense | $938 | -$792 | -$380 | $772 |
| Interest expense | $1626 | $1346 | $1300 | $1306 |
| Net income | ||||
| Net income | $5955 | $3288 | $115 | $3144 |
| Income (for common shares) | $5955 | $3288 | $115 | $3144 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $1927 | $2179 | $960 | $1374 |
| Operating activities | ||||
| Depreciation | $1279 | $1255 | $1327 | $1282 |
| Business acquisitions & disposals | -$2432 | -$940 | -$296 | -$258 |
| Stock-based compensation | ||||
| Total cash flows from operations | $3085 | $2486 | $2380 | $3114 |
| Investing activities | ||||
| Capital expenditures | -$382 | -$364 | -$524 | -$314 |
| Investments | $99 | -$57 | $109 | -$102 |
| Total cash flows from investing | -$2872 | -$2413 | -$1077 | -$1221 |
| Financing activities | ||||
| Dividends paid | -$17 | -$3033 | -$2 | -$1410 |
| Sale and purchase of stock | $5 | $6 | $21 | $4 |
| Net borrowings | -$1210 | $5063 | -$310 | -$1274 |
| Total cash flows from financing | -$1222 | $2028 | -$291 | -$2726 |
| Effect of exchange rate | -$6 | -$46 | $6 | -$19 |
| Change in cash and equivalents | -$1009 | $2101 | $1012 | -$833 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5955 | $3288 | $115 | $3144 |
| Operating activities | ||||
| Depreciation | $5387 | $5480 | $6530 | $3149 |
| Business acquisitions & disposals | -$989 | -$1061 | -$9413 | -$790 |
| Stock-based compensation | ||||
| Total cash flows from operations | $10345 | $9808 | $5963 | $4799 |
| Investing activities | ||||
| Capital expenditures | -$1229 | -$362 | -$1078 | -$855 |
| Investments | $97 | -$114 | $96 | $745 |
| Total cash flows from investing | -$4064 | -$2960 | -$11058 | -$285 |
| Financing activities | ||||
| Dividends paid | -$4481 | -$4364 | -$3856 | -$3572 |
| Sale and purchase of stock | $33 | $29 | $29 | $30 |
| Net borrowings | -$2100 | -$2361 | $7654 | $1440 |
| Total cash flows from financing | -$6567 | -$6823 | $3649 | -$2203 |
| Effect of exchange rate | -$60 | -$80 | -$62 | $12 |
| Change in cash and equivalents | -$286 | $25 | -$1446 | $2311 |
News
Fundamentals
| Market cap | $256.97B |
|---|---|
| Enterprise value | $283.59B |
| Shares outstanding | 3.08B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 6.50 |
| Book/Share | 12.82 |
| Cash/Share | 2.24 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.89 |
| Quick ratio | 0.69 |